SlideShare a Scribd company logo
Immunizing agents
Dr. Shubhangi Kshirsagar
Assistant Professor
Swasthavritta &Yoga department
Immunizing Agents
The immunizing agents may be classified as -
1. Vaccines
2. Immunoglobulins
3. Antisera
Vaccines
1. Vaccines
 Vaccine is an immuno-biological
substance when administered stimulates
production of antibody and protect
individual against particular disease.
 Vaccines are used for active
immunization.
Types of vaccine
1. Live
2. Killed
3. Subunit vaccine
4. Combined
Subunit vaccine
1. Toxoid
2. Protein vac
3. Recombinant protein vac
4. Polysaccharide based vac
5. Conjugated vac
1. Live vaccines
 Live vaccines are prepared from live or
wild (generally attenuated) organisms.
 These organisms are passed repeatedly in
the laboratory in tissue cultures or chick
embryos and have lost their capacity to
induce full blown disease but retain the
Immunogenicity.
 E.g BCG, Measles, Oral polio
6
Live Vaccines Are More Potent Immunizing
Agents Than Killed Vaccines Because
 Live organisms multiply in the host and the
resulting antigenic dose is larger than what is
injected.
 Have all the major and minor antigenic
components.
 Engage certain tissues of body (e.g. intestinal
mucosa by polio).
 Other mechanisms such as persistence of latent
virus.
Contraindication of live vaccine
 Immune deficiency disease
 Person whose immune response is suppressed
because of leukemia, lymphoma, malignancy
or therapy with corticosteroids, alkylating
agents, anti-metabolic agents or radiation
 Pregnancy
When two live vaccines are required they should
be given either simultaneously at different sites
or with an interval of at least three weeks.
Live vaccines
Bacterial Viral
BCG Oral polio
Typhoid oral Yellow fever
Measles
Rubella
Mumps
Influenza
2. Killed or inactivated vaccines
 Inactivated vaccines are produced by growing
virus or bacteria in culture media and then
inactivating them with heat or chemicals
(usually formalin)
 They stimulate active immunity.
 They are generally safe but less effective than
live vaccines.
 Killed vaccine require a series of 2-3 doses of
vaccine to produce adequate antibody
response.
 Most cases require booster dose.
 The duration of immunity - varies from
months to many years.
 Usually administered by subcutaneous or
intramuscular route.
 Contraindication - severe local or general
reaction to previous dose.
Inactivated or Killed Vaccines
12
Bacterial Viral
Typhoid Rabies
Cholera Salk polio
Pertusis Influenza
Plague Hepatitis A
Japanese encephalitis
3. Toxoids
 Certain organisms produce exotoxins e.g.
diphtheria and tetanus bacilli.
 The toxins produced by these organisms are
detoxicated and used in preparation of the
vaccines.
 The antibodies produced neutralize the toxin
produced during the infection.
 The toxoid act against the toxin rather than act
on the organism.
 Toxoid preparations are highly efficacious and
safe immunizing agents.
 E.g. Dipththeria, tetanus
4. Combined vaccines
 If more than one kind of immunizing agent is
included in the vaccine it is called a mixed or
combined vaccine.
 The aim of combined vaccines is to simplify
administration, reduce costs minimize the
number of contacts of the patient
with the health system, reducing the storage
cost, improving timelines of vaccination and
facilitating the addition of new
vaccine into immunization programme.
Examples of combined vaccines
 DPT (Diphtheria-pertussis-tetanus)
 DT (Diphtheria-tetanus)
 DP (Diphtheria-pertussis)
 DPT and typhoid vaccine
 MMR (Measles, mumps and rubella)
 DPTP (DPT + inactivated polio)
 Hepatitis A, and B
 Hepatitis A, and typhoid
 DTwP (Diphtheria, tetanus, whole-cell pertussis)
 DPT-Hep B-Hib (Diphtheria, pertussis, tetanus,
hepatitis B and haemophilus influenza type B)
Immunoglobulines
2. Immunoglobulines
 The human immunoglobulin system is
composed of 5 major classes (IgG, IgM,
IgA, IgD and IgE) and sub-classes
within them.
 The various classes and sub-classes of
immunoglobulins represent different
functional groups that are required to
meet different types of antigenic
challenges.
1. IgG
 80%
 Major immunoglobuline
 Antibodies to gram +ve
pyogenic bacteria
 Antiviral, antitoxic
antibodies are found in
IgG
 Half life - 21 days
 Extra-vascular
 Transported across
placenta
2. IgA
 13%
 Found in body secretion
e.g. saliva, milk, colostrum,
tears, bronchial secretion,
mucus secretion of
intestine
 Half life -6-8 days
 It provides primary defense
mechanism at mucus
membrane against local
infection
3. IgE
 <0.0005%
 Found in submucus
tissue
 Responsible for
immediate allergic
anaphylactic reaction
 Increase in Helminthes
infestation
 Half life -2days
4. IgM
 6%
 It represents antibody that is
promptly formed with
exposure to antigen
 Its presence may be
indicative of recent infection
 High agglutinating &
complement fixing ability.
 Can be produced by fetus
undergoing infection
 Half life -7days
5. IgD
 < 0.0003mg/ml
 Half life – 2 days.
 Act as antigen receptor when present on
certain B lymphocytes
Immunoglobuline preparation
 It is the readymade antibody preparation
obtained from human beings.
 It produces immediate immunity.
 These are used for passive immunization.
 These are -
a. Normal human immunoglobulin
b. Specific (hyper-immune) human
immunoglobulin
 These are used in the prophylaxis of viral
and bacterial infections and in replacement of
antibodies in immuno-deficient patients.
 Immunoglobulines are of two types -
1. Normal human immunoglobulin
2. Specific human immunoglobulin
Uses -
a. Used for prophylaxis of viral and
bacterial infection
b. Replacement of antibodies in immuno
deficient patients
a. Normal human immunoglobulin
 It is antibody rich fraction, obtained from pool of at
least 1000 donors.
 Prepared from plasma
 WHO standards for preparation NHIg
 Should contain 90% of intact IgG
 All IgG sub classes should be present
 Level of antibody against two bacterial species and two
virus.
 There should be a low lgA concentration
Uses –
1. For prevention of measles in highly susceptible contacts.
2. Temporary protection (12weeks) against Hepatitis A
infection in travelers.
b. Specific human immunoglobulin
 Prepared from the plasma of patients who have
recently recovered from an infection or are obtained
from individuals who have been immunized against a
specific infection.
 They therefore have a high antibody content against
an individual infection and provide immediate
protection e.g.
1. Chickenpox prophylaxis of highly susceptible
individuals
2. Hepatitis B - post exposure prophylaxis
3. Rabies
4. Tetanus prophylaxis
Adverse reaction of Immunoglobulines
1. Local – Pain, sterile abscess
2. Systemic –
a. Rapid
Occurs within minutes
Anaphylactic
b. Late
Occurs within hours or days
Urticaria, diarrhoea, pyrexia, arthralgia
Human Normal Ig Human Specific Ig Non Human
Antisera
Rabies Diphtheria
Hepatitis A Tetanus Tetanus
Measles Mumps Gas gangerene
Hepatitis B Botulism
Varicella Rabies
Diphtheria
Antisera or Antitoxins
3. Antisera or Antitoxins
 Antisera are the materials prepared from non-human
source like animals-horse.
 Used for passive immunization
 Less effective
 Immunity up to 2-3 week
 Antitoxins prepared from non human sources are
 Tetanus – ante tetanus serum
 Diphtheria- anti diptheria serum
 Anti snake venom
 Anti Gas gangrene serum
References
K. Park - preventive and social medicine
Thank You !

More Related Content

What's hot

Immunity host defences
Immunity   host defencesImmunity   host defences
Immunity host defences
Dr Shubhangi (Kshirsagar) Hedau
 
Immunization
ImmunizationImmunization
Immunization
philoarnold
 
Active and passive immunity
Active and passive immunityActive and passive immunity
Active and passive immunity
Daulal Chouhan
 
Japanese encephalitis epidemiology
Japanese encephalitis epidemiologyJapanese encephalitis epidemiology
Japanese encephalitis epidemiology
utpal sharma
 
Vector and rodent control
Vector and rodent controlVector and rodent control
Vector and rodent control
Namita Batra
 
Immunization
ImmunizationImmunization
Immunization
Akhilesh Bhargava
 
Dynamics of disease transmission
Dynamics of disease transmissionDynamics of disease transmission
Dynamics of disease transmission
frank jc
 
Vaccination and Immunization
Vaccination and ImmunizationVaccination and Immunization
Vaccination and Immunization
Numan Sharif
 
Vaccination
VaccinationVaccination
Vaccination
Sudhir Ben
 
Herd immunity
Herd immunityHerd immunity
Herd immunity
Daulal Chouhan
 
Vector born diseases
Vector born diseases  Vector born diseases
Vector born diseases
Muhammadasif909
 
Chikungunya fever
Chikungunya feverChikungunya fever
Chikungunya fever
Arifa T N
 
Plague.pptx
Plague.pptxPlague.pptx
Plague.pptx
Dr Bushra Jabeen
 
Levels of prevention
Levels of preventionLevels of prevention
Levels of prevention
Assistant Professor
 
National Immunization Schedule
National Immunization ScheduleNational Immunization Schedule
National Immunization Schedule
Manisha Mandal
 
Malaria
MalariaMalaria
Malaria
Swati Singh
 
BODY DEFENSES & IMMUNITY
BODY DEFENSES & IMMUNITYBODY DEFENSES & IMMUNITY
BODY DEFENSES & IMMUNITY
MAHESWARI JAIKUMAR
 
Cold chain system for vaccines
Cold chain system for vaccinesCold chain system for vaccines
Cold chain system for vaccines
ADESH MEDICAL COLLEGE
 

What's hot (20)

Immunity host defences
Immunity   host defencesImmunity   host defences
Immunity host defences
 
Immunization and vaccines
Immunization and vaccinesImmunization and vaccines
Immunization and vaccines
 
Immunization
ImmunizationImmunization
Immunization
 
Active and passive immunity
Active and passive immunityActive and passive immunity
Active and passive immunity
 
Japanese encephalitis epidemiology
Japanese encephalitis epidemiologyJapanese encephalitis epidemiology
Japanese encephalitis epidemiology
 
Vector and rodent control
Vector and rodent controlVector and rodent control
Vector and rodent control
 
Immunization
ImmunizationImmunization
Immunization
 
Dynamics of disease transmission
Dynamics of disease transmissionDynamics of disease transmission
Dynamics of disease transmission
 
Vaccination and Immunization
Vaccination and ImmunizationVaccination and Immunization
Vaccination and Immunization
 
Vaccination
VaccinationVaccination
Vaccination
 
Herd immunity
Herd immunityHerd immunity
Herd immunity
 
Vector born diseases
Vector born diseases  Vector born diseases
Vector born diseases
 
Chikungunya fever
Chikungunya feverChikungunya fever
Chikungunya fever
 
Plague.pptx
Plague.pptxPlague.pptx
Plague.pptx
 
Herd immunity
Herd immunityHerd immunity
Herd immunity
 
Levels of prevention
Levels of preventionLevels of prevention
Levels of prevention
 
National Immunization Schedule
National Immunization ScheduleNational Immunization Schedule
National Immunization Schedule
 
Malaria
MalariaMalaria
Malaria
 
BODY DEFENSES & IMMUNITY
BODY DEFENSES & IMMUNITYBODY DEFENSES & IMMUNITY
BODY DEFENSES & IMMUNITY
 
Cold chain system for vaccines
Cold chain system for vaccinesCold chain system for vaccines
Cold chain system for vaccines
 

Similar to Immunizing agents vaccines, immunoglobulines and antisera

Vaccines in children
Vaccines in childrenVaccines in children
Vaccines in children
Sujit Shrestha
 
Vaccination-A Veterinarian Perspective
Vaccination-A Veterinarian PerspectiveVaccination-A Veterinarian Perspective
Vaccination-A Veterinarian Perspective
Haroon Rashid Chaudhry
 
immunization-Vaccines,National immunization schedule.pptx
immunization-Vaccines,National immunization schedule.pptximmunization-Vaccines,National immunization schedule.pptx
immunization-Vaccines,National immunization schedule.pptx
anantaadityashivam
 
Vaccine delivery systems
Vaccine delivery systemsVaccine delivery systems
Vaccine delivery systems
JayeshRajput7
 
Immunity and vaccine (community medicine )
Immunity and vaccine (community medicine )Immunity and vaccine (community medicine )
Immunity and vaccine (community medicine )
Niko439610
 
vaccines-191201151736.pptx
vaccines-191201151736.pptxvaccines-191201151736.pptx
vaccines-191201151736.pptx
AbhishekKumar671692
 
Asha
AshaAsha
Vaccination
VaccinationVaccination
David Haselwood | How vaccines prevent diseases
David Haselwood | How vaccines prevent diseasesDavid Haselwood | How vaccines prevent diseases
David Haselwood | How vaccines prevent diseases
David Haselwood
 
UNIT 4 MIC.pptx
UNIT 4 MIC.pptxUNIT 4 MIC.pptx
UNIT 4 MIC.pptx
JyotiBhagat31
 
Vaccines (immunotherapy) & COVID-19 Overview
Vaccines (immunotherapy) & COVID-19 OverviewVaccines (immunotherapy) & COVID-19 Overview
Vaccines (immunotherapy) & COVID-19 Overview
Rishab Malhotra
 
Vaccine
VaccineVaccine
Vaccine
Salma Rokaya
 
Vaccine
VaccineVaccine
Vaccine
Salma Rokaya
 
Immunisation.pptx
Immunisation.pptxImmunisation.pptx
Immunisation.pptx
Rinki61
 
Antimicrobial agents and immunization immunotherapy
Antimicrobial agents and immunization  immunotherapyAntimicrobial agents and immunization  immunotherapy
Antimicrobial agents and immunization immunotherapy
Areej Abu Hanieh
 
vaccines vaccination
vaccines vaccinationvaccines vaccination
vaccines vaccination
SNEHADAS123
 
Study of immunological products
Study of  immunological productsStudy of  immunological products
Study of immunological products
SandhyaPunetha1
 
Immunity
ImmunityImmunity
Immunity
Shubham Parmar
 

Similar to Immunizing agents vaccines, immunoglobulines and antisera (20)

Vaccines in children
Vaccines in childrenVaccines in children
Vaccines in children
 
Vaccination-A Veterinarian Perspective
Vaccination-A Veterinarian PerspectiveVaccination-A Veterinarian Perspective
Vaccination-A Veterinarian Perspective
 
immunization-Vaccines,National immunization schedule.pptx
immunization-Vaccines,National immunization schedule.pptximmunization-Vaccines,National immunization schedule.pptx
immunization-Vaccines,National immunization schedule.pptx
 
Vaccine delivery systems
Vaccine delivery systemsVaccine delivery systems
Vaccine delivery systems
 
Immunity and vaccine (community medicine )
Immunity and vaccine (community medicine )Immunity and vaccine (community medicine )
Immunity and vaccine (community medicine )
 
Immune response & uip
Immune response & uipImmune response & uip
Immune response & uip
 
vaccines-191201151736.pptx
vaccines-191201151736.pptxvaccines-191201151736.pptx
vaccines-191201151736.pptx
 
Asha
AshaAsha
Asha
 
Vaccination
VaccinationVaccination
Vaccination
 
David Haselwood | How vaccines prevent diseases
David Haselwood | How vaccines prevent diseasesDavid Haselwood | How vaccines prevent diseases
David Haselwood | How vaccines prevent diseases
 
UNIT 4 MIC.pptx
UNIT 4 MIC.pptxUNIT 4 MIC.pptx
UNIT 4 MIC.pptx
 
Vaccines (immunotherapy) & COVID-19 Overview
Vaccines (immunotherapy) & COVID-19 OverviewVaccines (immunotherapy) & COVID-19 Overview
Vaccines (immunotherapy) & COVID-19 Overview
 
Vaccine
VaccineVaccine
Vaccine
 
Vaccine
VaccineVaccine
Vaccine
 
Immunisation.pptx
Immunisation.pptxImmunisation.pptx
Immunisation.pptx
 
Antimicrobial agents and immunization immunotherapy
Antimicrobial agents and immunization  immunotherapyAntimicrobial agents and immunization  immunotherapy
Antimicrobial agents and immunization immunotherapy
 
vaccines vaccination
vaccines vaccinationvaccines vaccination
vaccines vaccination
 
Study of immunological products
Study of  immunological productsStudy of  immunological products
Study of immunological products
 
Immunity
ImmunityImmunity
Immunity
 
Biologics
BiologicsBiologics
Biologics
 

More from Dr Shubhangi (Kshirsagar) Hedau

RNTCP programme.pdf
RNTCP programme.pdfRNTCP programme.pdf
RNTCP programme.pdf
Dr Shubhangi (Kshirsagar) Hedau
 
National Leprosy Eradication programme.pdf
National Leprosy Eradication programme.pdfNational Leprosy Eradication programme.pdf
National Leprosy Eradication programme.pdf
Dr Shubhangi (Kshirsagar) Hedau
 
World health organisation.pdf
World health organisation.pdfWorld health organisation.pdf
World health organisation.pdf
Dr Shubhangi (Kshirsagar) Hedau
 
Epidemiology of Cholera
Epidemiology of CholeraEpidemiology of Cholera
Epidemiology of Cholera
Dr Shubhangi (Kshirsagar) Hedau
 
Typhoid fever
Typhoid feverTyphoid fever
Lymphatic filariasis
Lymphatic filariasisLymphatic filariasis
Lymphatic filariasis
Dr Shubhangi (Kshirsagar) Hedau
 
Epidemiology of Malaria
Epidemiology of MalariaEpidemiology of Malaria
Epidemiology of Malaria
Dr Shubhangi (Kshirsagar) Hedau
 
Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome (SARS)Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome (SARS)
Dr Shubhangi (Kshirsagar) Hedau
 
Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)
Dr Shubhangi (Kshirsagar) Hedau
 
Diptheria
DiptheriaDiptheria
Mumps
MumpsMumps
Measles
Measles Measles
Vital statistics health statistics
Vital statistics   health statisticsVital statistics   health statistics
Vital statistics health statistics
Dr Shubhangi (Kshirsagar) Hedau
 
Epidemiology of tuberculosis
Epidemiology of tuberculosisEpidemiology of tuberculosis
Epidemiology of tuberculosis
Dr Shubhangi (Kshirsagar) Hedau
 
Concept & levels of prevention
Concept & levels of preventionConcept & levels of prevention
Concept & levels of prevention
Dr Shubhangi (Kshirsagar) Hedau
 
Disinfection
DisinfectionDisinfection
Modes of intervention
Modes of interventionModes of intervention
Modes of intervention
Dr Shubhangi (Kshirsagar) Hedau
 
Concpt &amp; levels of prevention
Concpt &amp; levels of preventionConcpt &amp; levels of prevention
Concpt &amp; levels of prevention
Dr Shubhangi (Kshirsagar) Hedau
 
Epidemiology of leprosy
Epidemiology of leprosyEpidemiology of leprosy
Epidemiology of leprosy
Dr Shubhangi (Kshirsagar) Hedau
 
Primary health care
Primary health carePrimary health care
Primary health care
Dr Shubhangi (Kshirsagar) Hedau
 

More from Dr Shubhangi (Kshirsagar) Hedau (20)

RNTCP programme.pdf
RNTCP programme.pdfRNTCP programme.pdf
RNTCP programme.pdf
 
National Leprosy Eradication programme.pdf
National Leprosy Eradication programme.pdfNational Leprosy Eradication programme.pdf
National Leprosy Eradication programme.pdf
 
World health organisation.pdf
World health organisation.pdfWorld health organisation.pdf
World health organisation.pdf
 
Epidemiology of Cholera
Epidemiology of CholeraEpidemiology of Cholera
Epidemiology of Cholera
 
Typhoid fever
Typhoid feverTyphoid fever
Typhoid fever
 
Lymphatic filariasis
Lymphatic filariasisLymphatic filariasis
Lymphatic filariasis
 
Epidemiology of Malaria
Epidemiology of MalariaEpidemiology of Malaria
Epidemiology of Malaria
 
Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome (SARS)Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome (SARS)
 
Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)
 
Diptheria
DiptheriaDiptheria
Diptheria
 
Mumps
MumpsMumps
Mumps
 
Measles
Measles Measles
Measles
 
Vital statistics health statistics
Vital statistics   health statisticsVital statistics   health statistics
Vital statistics health statistics
 
Epidemiology of tuberculosis
Epidemiology of tuberculosisEpidemiology of tuberculosis
Epidemiology of tuberculosis
 
Concept & levels of prevention
Concept & levels of preventionConcept & levels of prevention
Concept & levels of prevention
 
Disinfection
DisinfectionDisinfection
Disinfection
 
Modes of intervention
Modes of interventionModes of intervention
Modes of intervention
 
Concpt &amp; levels of prevention
Concpt &amp; levels of preventionConcpt &amp; levels of prevention
Concpt &amp; levels of prevention
 
Epidemiology of leprosy
Epidemiology of leprosyEpidemiology of leprosy
Epidemiology of leprosy
 
Primary health care
Primary health carePrimary health care
Primary health care
 

Recently uploaded

the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
ssuser787e5c1
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
PGIMS Rohtak
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
SasikiranMarri
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cell
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
priyabhojwani1200
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
Kumar Satyam
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
AnushriSrivastav
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
o6ov5dqmf
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 
Yemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .pptYemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .ppt
Esam43
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
Iris Thiele Isip-Tan
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
Aboud Health Group
 
Roti bank chennai PPT [Autosaved].pptx1
Roti bank  chennai PPT [Autosaved].pptx1Roti bank  chennai PPT [Autosaved].pptx1
Roti bank chennai PPT [Autosaved].pptx1
roti bank
 
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
samahesh1
 

Recently uploaded (20)

the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 
Yemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .pptYemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .ppt
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
 
Roti bank chennai PPT [Autosaved].pptx1
Roti bank  chennai PPT [Autosaved].pptx1Roti bank  chennai PPT [Autosaved].pptx1
Roti bank chennai PPT [Autosaved].pptx1
 
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
 

Immunizing agents vaccines, immunoglobulines and antisera

  • 1. Immunizing agents Dr. Shubhangi Kshirsagar Assistant Professor Swasthavritta &Yoga department
  • 2. Immunizing Agents The immunizing agents may be classified as - 1. Vaccines 2. Immunoglobulins 3. Antisera
  • 4. 1. Vaccines  Vaccine is an immuno-biological substance when administered stimulates production of antibody and protect individual against particular disease.  Vaccines are used for active immunization.
  • 5. Types of vaccine 1. Live 2. Killed 3. Subunit vaccine 4. Combined Subunit vaccine 1. Toxoid 2. Protein vac 3. Recombinant protein vac 4. Polysaccharide based vac 5. Conjugated vac
  • 6. 1. Live vaccines  Live vaccines are prepared from live or wild (generally attenuated) organisms.  These organisms are passed repeatedly in the laboratory in tissue cultures or chick embryos and have lost their capacity to induce full blown disease but retain the Immunogenicity.  E.g BCG, Measles, Oral polio 6
  • 7. Live Vaccines Are More Potent Immunizing Agents Than Killed Vaccines Because  Live organisms multiply in the host and the resulting antigenic dose is larger than what is injected.  Have all the major and minor antigenic components.  Engage certain tissues of body (e.g. intestinal mucosa by polio).  Other mechanisms such as persistence of latent virus.
  • 8. Contraindication of live vaccine  Immune deficiency disease  Person whose immune response is suppressed because of leukemia, lymphoma, malignancy or therapy with corticosteroids, alkylating agents, anti-metabolic agents or radiation  Pregnancy When two live vaccines are required they should be given either simultaneously at different sites or with an interval of at least three weeks.
  • 9. Live vaccines Bacterial Viral BCG Oral polio Typhoid oral Yellow fever Measles Rubella Mumps Influenza
  • 10. 2. Killed or inactivated vaccines  Inactivated vaccines are produced by growing virus or bacteria in culture media and then inactivating them with heat or chemicals (usually formalin)  They stimulate active immunity.  They are generally safe but less effective than live vaccines.  Killed vaccine require a series of 2-3 doses of vaccine to produce adequate antibody response.  Most cases require booster dose.
  • 11.  The duration of immunity - varies from months to many years.  Usually administered by subcutaneous or intramuscular route.  Contraindication - severe local or general reaction to previous dose.
  • 12. Inactivated or Killed Vaccines 12 Bacterial Viral Typhoid Rabies Cholera Salk polio Pertusis Influenza Plague Hepatitis A Japanese encephalitis
  • 13. 3. Toxoids  Certain organisms produce exotoxins e.g. diphtheria and tetanus bacilli.  The toxins produced by these organisms are detoxicated and used in preparation of the vaccines.  The antibodies produced neutralize the toxin produced during the infection.  The toxoid act against the toxin rather than act on the organism.  Toxoid preparations are highly efficacious and safe immunizing agents.  E.g. Dipththeria, tetanus
  • 14. 4. Combined vaccines  If more than one kind of immunizing agent is included in the vaccine it is called a mixed or combined vaccine.  The aim of combined vaccines is to simplify administration, reduce costs minimize the number of contacts of the patient with the health system, reducing the storage cost, improving timelines of vaccination and facilitating the addition of new vaccine into immunization programme.
  • 15. Examples of combined vaccines  DPT (Diphtheria-pertussis-tetanus)  DT (Diphtheria-tetanus)  DP (Diphtheria-pertussis)  DPT and typhoid vaccine  MMR (Measles, mumps and rubella)  DPTP (DPT + inactivated polio)  Hepatitis A, and B  Hepatitis A, and typhoid  DTwP (Diphtheria, tetanus, whole-cell pertussis)  DPT-Hep B-Hib (Diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type B)
  • 17. 2. Immunoglobulines  The human immunoglobulin system is composed of 5 major classes (IgG, IgM, IgA, IgD and IgE) and sub-classes within them.  The various classes and sub-classes of immunoglobulins represent different functional groups that are required to meet different types of antigenic challenges.
  • 18. 1. IgG  80%  Major immunoglobuline  Antibodies to gram +ve pyogenic bacteria  Antiviral, antitoxic antibodies are found in IgG  Half life - 21 days  Extra-vascular  Transported across placenta 2. IgA  13%  Found in body secretion e.g. saliva, milk, colostrum, tears, bronchial secretion, mucus secretion of intestine  Half life -6-8 days  It provides primary defense mechanism at mucus membrane against local infection
  • 19. 3. IgE  <0.0005%  Found in submucus tissue  Responsible for immediate allergic anaphylactic reaction  Increase in Helminthes infestation  Half life -2days 4. IgM  6%  It represents antibody that is promptly formed with exposure to antigen  Its presence may be indicative of recent infection  High agglutinating & complement fixing ability.  Can be produced by fetus undergoing infection  Half life -7days
  • 20. 5. IgD  < 0.0003mg/ml  Half life – 2 days.  Act as antigen receptor when present on certain B lymphocytes
  • 21. Immunoglobuline preparation  It is the readymade antibody preparation obtained from human beings.  It produces immediate immunity.  These are used for passive immunization.  These are - a. Normal human immunoglobulin b. Specific (hyper-immune) human immunoglobulin  These are used in the prophylaxis of viral and bacterial infections and in replacement of antibodies in immuno-deficient patients.
  • 22.  Immunoglobulines are of two types - 1. Normal human immunoglobulin 2. Specific human immunoglobulin Uses - a. Used for prophylaxis of viral and bacterial infection b. Replacement of antibodies in immuno deficient patients
  • 23. a. Normal human immunoglobulin  It is antibody rich fraction, obtained from pool of at least 1000 donors.  Prepared from plasma  WHO standards for preparation NHIg  Should contain 90% of intact IgG  All IgG sub classes should be present  Level of antibody against two bacterial species and two virus.  There should be a low lgA concentration Uses – 1. For prevention of measles in highly susceptible contacts. 2. Temporary protection (12weeks) against Hepatitis A infection in travelers.
  • 24. b. Specific human immunoglobulin  Prepared from the plasma of patients who have recently recovered from an infection or are obtained from individuals who have been immunized against a specific infection.  They therefore have a high antibody content against an individual infection and provide immediate protection e.g. 1. Chickenpox prophylaxis of highly susceptible individuals 2. Hepatitis B - post exposure prophylaxis 3. Rabies 4. Tetanus prophylaxis
  • 25. Adverse reaction of Immunoglobulines 1. Local – Pain, sterile abscess 2. Systemic – a. Rapid Occurs within minutes Anaphylactic b. Late Occurs within hours or days Urticaria, diarrhoea, pyrexia, arthralgia
  • 26. Human Normal Ig Human Specific Ig Non Human Antisera Rabies Diphtheria Hepatitis A Tetanus Tetanus Measles Mumps Gas gangerene Hepatitis B Botulism Varicella Rabies Diphtheria
  • 28. 3. Antisera or Antitoxins  Antisera are the materials prepared from non-human source like animals-horse.  Used for passive immunization  Less effective  Immunity up to 2-3 week  Antitoxins prepared from non human sources are  Tetanus – ante tetanus serum  Diphtheria- anti diptheria serum  Anti snake venom  Anti Gas gangrene serum
  • 29. References K. Park - preventive and social medicine